Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil falls 1% as investors watch Middle East supply disruptions
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Cyclacel Pharmaceuticals, Inc. (CYCC) Posts Q4 Loss of 19c/Share
March 25, 2014 4:05 PM EDTCyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) reported Q4 EPS of ($0.19), $0.14 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $299 thousand versus the consensus estimate of $90 thousand.
For earnings history and earnings-related data on Cyclacel Pharmaceuticals, Inc. (CYCC) click here.... More
